DiaMedica Therapeutics Inc.
DMAC
$3.75
-$0.10-2.60%
NASDAQ
03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
---|---|---|---|---|---|
Revenue | -- | -- | -- | -- | -- |
Total Other Revenue | -- | -- | -- | -- | -- |
Total Revenue | -- | -- | -- | -- | -- |
Cost of Revenue | -- | -- | -- | -- | -- |
Gross Profit | -- | -- | -- | -- | -- |
SG&A Expenses | 2.49M | 1.95M | 1.90M | 1.71M | 2.07M |
Depreciation & Amortization | -- | -- | -- | -- | -- |
Other Operating Expenses | -- | -- | -- | -- | -- |
Total Operating Expenses | 8.14M | 8.42M | 6.88M | 5.64M | 5.74M |
Operating Income | -8.14M | -8.42M | -6.88M | -5.64M | -5.74M |
Income Before Tax | -7.70M | -7.89M | -6.27M | -5.11M | -5.14M |
Income Tax Expenses | 6.00K | 9.00K | 7.00K | 7.00K | 7.00K |
Earnings from Continuing Operations | -7.71M | -7.90M | -6.27M | -5.12M | -5.15M |
Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
Minority Interest in Earnings | -- | -- | -- | -- | -- |
Net Income | -7.71M | -7.90M | -6.27M | -5.12M | -5.15M |
EBIT | -8.14M | -8.42M | -6.88M | -5.64M | -5.74M |
EBITDA | -8.13M | -8.41M | -6.87M | -5.63M | -5.73M |
EPS Basic | -0.18 | -0.18 | -0.15 | -0.13 | -0.14 |
Normalized Basic EPS | -0.11 | -0.12 | -0.09 | -0.08 | -0.08 |
EPS Diluted | -0.18 | -0.18 | -0.15 | -0.13 | -0.14 |
Normalized Diluted EPS | -0.11 | -0.12 | -0.09 | -0.08 | -0.08 |
Average Basic Shares Outstanding | 42.84M | 42.81M | 42.75M | 38.07M | 37.96M |
Average Diluted Shares Outstanding | 42.84M | 42.81M | 42.75M | 38.07M | 37.96M |
Dividend Per Share | -- | -- | -- | -- | -- |
Payout Ratio | -- | -- | -- | -- | -- |